Cargando…

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Introduction: The COVID-19 pandemic reflects liver damage. A study carried out in China (Guan WJ et al. N Engl J Med. 2020) reported that in more than 21% of cases there was an elevation of liver enzymes (ELE), with only 2.1% of them having previous liver disease. ELE is frequent in anticoagulated p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerezo Manchado, Juan Jose, Olivera, Pável E, Lopez Abellan, María Dolores, Campoy Castaño, Desiree, Velasquez, César A, Rodriguez Rojas, Carlos, Ramos Arenas, Veronica, Flores, Katia, Cárdenas Gámez, Rubén, García de Guadiana Romualdo, Luis, Iturbe Hernandez, Teodoro, Sierra, Jorge, Salinas, Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	332.Anticoagulation and Antithrombotic Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330343/ http://dx.doi.org/10.1182/blood-2020-142451

Ejemplares similares

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
por: Mughal, Mohsin Sheraz, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
por: Gonzalez-Ochoa, Alejandro
Publicado: (2021)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Rapid ECMO Training for Nurses in Response to the COVID-19 Pandemic
por: Toy, B., et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
por: Cerezo Manchado, Juan José, et al.
Publicado: (2023)

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol
por: Iturbe-Hernandez, Teodoro, et al.
Publicado: (2020)

Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol
por: Cerezo-Manchado, Juan José, et al.
Publicado: (2022)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
por: Olivera, Pável, et al.
Publicado: (2023)

Increased concentrations of procalcitonin in patients with paracetamol intoxication
por: García de Guadiana Romualdo, Luis, et al.
Publicado: (2021)

Incremento de las concentraciones de procalcitonina en pacientes intoxicados por paracetamol
por: García de Guadiana-Romualdo, Luis, et al.
Publicado: (2020)

IMMUNE THROMBOCYTOPENIA PURPURA FLARE POST SARS-COV-2 VACCINATION
por: Ali, Elrazi, et al.
Publicado: (2021)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related strokes and mortality
por: Kang, D S, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related bleeding and mortality
por: Kang, D S, et al.
Publicado: (2023)

Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation or left sided atrial tachycardia in patients on oral anticoagulation
por: Maslova, V, et al.
Publicado: (2023)

Impact of concomitant proton pump inhibitor during oral anticoagulant treatment
por: Lee, K N, et al.
Publicado: (2023)

Identification of a real-world clinical model associated with atrial fibrillation in a large french primary care database
por: Sabouret, S P F, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
por: Santoro, F, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dgmm1geegt1ji459786hik5lq3